Primmune Therapeutics
Carlsbad, US · Founded 2017 · 9 employees on LinkedIn · 4 known investors
Find your way into Primmune Therapeutics
6 people in our graph share verified history with the Primmune Therapeutics team — schools, employers, funds. One of them is your warm intro.
Debora Dumontunlockedknows Paulo Rangel · together at Primmune Therapeutics (overlapped)
×2knows the team · via Primmune Therapeutics
×2knows the team · via Besins Healthcare
knows the team · via Evince Biosciences
Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
Founders & leadership
Primmune Therapeutics was founded in 2017 by James Appleman, Paulo Rangel, and Stephen Webber.
JA
James ApplemanSVP, R&D and CSO, Cofounder
PR
Paulo RangelinChief Business Officer and CofounderHe brings experience in pharmaceutical and medical device business development, including licensing, valuations, clinical trials, and intellectual property management, and holds an MBA from Duke University and a BA in Chemistry/Biochemistry from UC San Diego.
SW
Stephen WebberinVice President, Medicinal Chemistry, and Cofounder
CM
Charles McDermottPresident & CEO, Director
Board
TJ
Todd J HarrisBoard director
Investors · 4
Reported raises · per SEC filings
Form D private placements$20.1M disclosed across 5 rounds · 2017–2020
▶$13MraisedNov 2020 · 12 investors · PharmaceuticalsRule 506(b)
▶$13MraisedNov 2020 · 12 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer
- Scott MorensteinDirector
- Andrew RubinsteinDirector
- Amir NashatDirector
- Offering amount
- $24M
- Amount sold
- $13M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.1MraisedMar 2020 · 19 investors · PharmaceuticalsRule 506(b)
▶$1.1MraisedMar 2020 · 19 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $4M
- Amount sold
- $1.1M
- First sale
- Jul 2018
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2MraisedMar 2020 · 17 investors · PharmaceuticalsRule 506(b)
▶$2MraisedMar 2020 · 17 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $4M
- Amount sold
- $2M
- First sale
- Feb 2019
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$2.5MraisedMar 2020 · 2 investors · PharmaceuticalsRule 506(b)
▶$2.5MraisedMar 2020 · 2 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Charles McDermottExecutive Officer, Director
- James R. ApplemanExecutive Officer, Director
- Todd J. HarrisDirector
- Paulo S. RangelExecutive Officer, Director
- Scott MorensteinDirector
- Offering amount
- $3.5M
- Amount sold
- $2.5M
- First sale
- Feb 2020
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$1.5MraisedJan 2018 · 36 investors · Other TechnologyRule 506(b)
▶$1.5MraisedJan 2018 · 36 investors · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- Todd J HarrisDirector
- Paulo S RangelExecutive Officer, Director
- James R ApplemanExecutive Officer, Director
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- Proceeds to insiders
- $360K
- First sale
- Oct 2017
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Primmune Therapeutics do?
- Primmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.
- Who founded Primmune Therapeutics?
- Primmune Therapeutics was founded by James Appleman, Paulo Rangel, Stephen Webber in 2017.
- Who are Primmune Therapeutics's investors?
- Primmune Therapeutics's investors include BioBrit, BioRock Ventures, Samsara BioCapital, Polaris Partners.
- How much funding has Primmune Therapeutics raised?
- Primmune Therapeutics has disclosed $20.1M raised across 5 rounds.
- Where is Primmune Therapeutics headquartered?
- Primmune Therapeutics is headquartered in Carlsbad, US.